Please login to the form below

Not currently logged in

Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients

Renal cell carcinoma is the most common form of kidney cancer

Merck & Co – known as MSD outside the US and Canada – has announced that its PD-1 inhibitor Keytruda plus Eisai’s Lenvima improved outcomes versus Pfizer’s Sutent on a measure of health-related quality of life in a phase 3 trial in first-line renal cell carcinoma (RCC) – the most common form of kidney cancer.

The new data, presented at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, comes from the CLEAR/KEYNOTE-581 study, which is evaluating Lenvima (lenvatinib) plus Keytruda (pembrolizumab) or Novartis’ Afinitor (everolimus) versus Sutent (sunitinib) for the first-line treatment of advanced RCC patients.

Analysis of a secondary endpoints – health-related quality of life (HRQoL) based on patient-reported outcomes – found that Keytruda plus Lenvima demonstrated similar changes from baseline at week 46 on 14 out of 18 HRQoL and disease-related symptoms scores, as well as better HRQoL and disease-related symptoms scores for physical functioning, fatigue, dyspnea and constipation versus Sutent.

In addition, Lenvima plus Afinitor also demonstrated similar changes from baseline at week 46 on 14 out of 18 HRQoL and disease-related symptom scores, as well as a delay in time to first deterioration (TTD) for physical functioning, dyspnea, appetite loss and the EQ-5D visual analog scale compared to Sutent.

“We continue to see an increasing number of patients diagnosed with advanced renal cell carcinoma and remain committed to improving outcomes for those facing this difficult-to-treat disease,” said Gregory Lubiniecki, vice president, oncology clinical research, Merck Research Laboratories.

“This new analysis builds on earlier findings from the CLEAR/KEYNOTE-581 trial and further supports the potential use of Keytruda plus Lenvima for the treatment of patients in the first-line setting,” he added.

“This analysis addresses questions of interest to healthcare professionals who treat patients with advanced renal cell carcinoma and reinforces the Keytruda plus Lenvima combination as a possible new treatment option for patients with this disease,” said Takashi Owa, chief medicine creation officer and chief discovery officer, Oncology Business Group at Eisai.

“These results reflect Eisai and Merck’s shared commitment to relentlessly pursue thorough scientific investigations the goal of improving cancer care,” he added.

Previously, Merck and Eisai reported that Keytruda and Lenvima met the primary endpoint of improved progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib) in first-line advanced RCC patients.

The combination treatment also met key secondary endpoints of overall survival (OS) and objective response rate (ORR).

When administered alongside Lenvima, Keytruda demonstrated a statistically significant and clinically meaningful improvement on all counts – including PFS, OS and ORR.

Article by
Lucy Parsons

7th June 2021

From: Research



Subscribe to our email news alerts


Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...